Data of US postmenopausal women with normal BMI show that trunk fat and higher leg fat have opposing associations with CVD risk, while total body fat was not significantly related to CVD risk.
ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.
ESC 2019 The PURE study shows that in high-income countries, cancer accounts for more deaths than CVD, while in low-income countries CVD mortality is higher, although risk factors are lower there.
ESC 2019 Using genetic scores to assess lifelong exposure to LDL-c and SBP levels, suggests that relatively small differences in this exposure associated large proportional risk reductions.
The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?
In the SMART population, smoking cessation after an event resulted in about 5 years longer survival and delay of recurrent events by about 10 years, compared to those who continue to smoke.
The European Association of Preventive Cardiology reviewed various online risk prediction algorithms and considers advantages and caveats, and gives guidance on which tool to use for which patient.
CLARIFY registry data suggest that beta-blocker use was only associated with lower 5-year mortality in patients enrolled in the year following in MI. Use of calcium antagonists did not impact mortality.
EAS 2019 Prof. Chris Packard distinguishes various types of biomarkers. Thinking about them in this way can provide a framework for more intelligent use of biomarkers.
The LIFE-CVD model can assess 10-year and lifetime CVD risk and life-years gained free from CVD and the effect of interventions in apparently healthy people.
The PCP-HF score provides sex- and race-specific estimates of 10-year risk of incident HF, based on risk factor information readily available in primary care setting.
ADA 2019 The REWIND trial, which included a majority of participants without established CVD, showed that dulaglutide treatment resulted in 12% reduction in MACE, irrespective of history of CVD.